Clinical Trial Update: A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

Phase I study evaluating safety and tolerability of JL15003 injection in patients with recurrent glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• JL15003

Snippet

Sponsor: Jecho Biopharmaceuticals Co., Ltd. | Conditions: Recurrent Glioblastoma Multiforme(GBM) | Phase 1 | Status: COMPLETED